HSBC Holdings
TBPH icon

HSBC Holdings’s Theravance Biopharma TBPH Stock Holding History

HSBC Holdings’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$696K Buy
43,204
+24,727
+134% +$437K ﹤0.01% 2051
2025
Q4 		$354K Sell
18,477
-30,440
-62% -$505K ﹤0.01% 2458
2025
Q3 		$719K Sell
48,917
-8,297
-15% -$105K ﹤0.01% 1931
2025
Q2 		$638K Buy
+57,214
New +$556K ﹤0.01% 2024
2024
Q3 		– Sell
-12,829
Closed -$108K – 3154
2024
Q2 		$108K Buy
+12,829
New +$116K ﹤0.01% 2716
2021
Q2 		– Sell
-10,412
Closed -$210K – 3079
2021
Q1 		$210K Sell
10,412
-1,718
-14% -$32.7K ﹤0.01% 2524
2020
Q4 		$212K Hold
12,130
– – ﹤0.01% 2784
2020
Q3 		$183K Hold
12,130
– – ﹤0.01% 2498
2020
Q2 		$254K Sell
12,130
-774
-6% -$19.9K ﹤0.01% 2216
2020
Q1 		$298K Buy
12,904
+3,759
+41% +$94.1K ﹤0.01% 2063
2019
Q4 		$240K Buy
+9,145
New +$178K ﹤0.01% 2706
2017
Q1 		– Sell
-6,914
Closed -$220K – 2558
2016
Q4 		$220K Buy
+6,914
New +$214K ﹤0.01% 2468

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's TBPH Position: Q1 2026 in Review

HSBC Holdings increased its Theravance Biopharma (TBPH) stake by 134% in Q1 2026, buying an estimated $437K and bringing the position to 43,204 shares worth $696K. The position accounts for ﹤0.01% of the portfolio, ranked #2051.

HSBC Holdings first reported a position in TBPH in Q4 2016 and has held it in 12 quarters since. The position peaked at $719K in Q3 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • HSBC Holdings held 43,204 shares of Theravance Biopharma worth $696K as of Q1 2026.
  • HSBC Holdings bought 24,727 Theravance Biopharma shares in Q1 2026, an estimated $437K.
  • Theravance Biopharma made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2051 holding.
  • HSBC Holdings first reported a position in Theravance Biopharma in Q4 2016 and has held it in 12 quarters since.
  • HSBC Holdings's Theravance Biopharma position peaked at $719K in Q3 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.